Ezquieta B, Luzuriaga Cristina
Laboratorio de Diagnóstico Molecular, Servicio de Bioquímica, Hospital G. U. 'Gregorio Marañón', Madrid, Spain.
Clin Genet. 2004 Sep;66(3):229-35. doi: 10.1111/j.1399-0004.2004.00291.x.
This article reports the case of a boy diagnosed at 1.8 years of age with congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. The patient showed salt-wasting episodes during the neonatal period. On molecular analysis, a homozygous deletion hybrid (CYP11B2-CYP11B1) involving the CYP11B locus at 8q24.3 was found. Southern blot analysis showed the break point of the chimera gene to be located before intron 5; sequence analysis identified it at exon 4 between codons 202 and 248. This CYP11B2(5')/B1(3') hybrid should lack aldosterone synthase activity (due to the CYP11B1 residues at exons 5 and 6), and the enzyme it codes for should not be promoted by adrenocorticotropic hormone (ACTH) (CYP11B2 promoter sequences). The patient phenotype - neonatal salt-wasting and 11 beta-hydroxylase deficiency - is in agreement with this hybrid structure. This is the first time a homozygous deletion hybrid generated by unequal crossover has been described in exon 4. This genetic lesion appears to be the reciprocal product from the recombination event that causes glucocorticoid-remediable aldosteronism, a duplication dominant allele (CYP11B2-CYP11B1/B2-CYP11B1) coding for additional aldosterone synthase activity regulated by ACTH. The clinical presentation of the condition in this patient contributes to the in vivo understanding of the regulation of this complex locus in which two 'duplicated' genes have evolved different regulatory and enzymatic activities involved in mineralocorticoid and glucocorticoid synthesis in the adrenal glands. The fact that this allele was first predicted and has now been documented clinically and molecularly in vivo is particularly noteworthy.
本文报告了一名1.8岁男孩的病例,该男孩被诊断为因11β-羟化酶缺乏导致的先天性肾上腺皮质增生症。患者在新生儿期出现失盐发作。分子分析发现,在8q24.3处涉及CYP11B基因座的纯合缺失杂种(CYP11B2-CYP11B1)。Southern印迹分析显示嵌合基因的断点位于内含子5之前;序列分析确定其位于外显子4中密码子202和248之间。这种CYP11B2(5')/B1(3')杂种应该缺乏醛固酮合成酶活性(由于外显子5和6处的CYP11B1残基),并且其编码的酶不应被促肾上腺皮质激素(ACTH)促进(CYP11B2启动子序列)。患者的表型——新生儿失盐和11β-羟化酶缺乏——与这种杂种结构一致。这是首次在外显子4中描述由不等交换产生的纯合缺失杂种。这种基因病变似乎是导致糖皮质激素可纠正醛固酮增多症的重组事件的相互产物,一种编码受ACTH调节的额外醛固酮合成酶活性的重复显性等位基因(CYP11B2-CYP11B1/B2-CYP11B1)。该患者病情的临床表现有助于在体内理解这个复杂基因座的调控,其中两个“重复”基因已经进化出参与肾上腺盐皮质激素和糖皮质激素合成的不同调控和酶活性。这个等位基因首先被预测,现在已在临床和体内分子水平得到证实,这一事实尤其值得注意。